Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy

Current Opinion in Supportive and Palliative Care

Volumn 2, Issue 1, 2008, Pages 28-34

  Ellebæk, Eva ^a   Herrstedt, JØrn ^b  

^a Mental Health Center Glostrup   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antiemetics; Multiple cycles; Multiple day chemotherapy; Nausea; Vomiting

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CISPLATIN; DEXAMETHASONE; DOPAMINE 2 RECEPTOR; ISONIPECOTIC ACID; ISOQUINOLINE DERIVATIVE; METOPIMAZINE; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR; OLANZAPINE; PALONOSETRON; QUINUCLIDINE DERIVATIVE; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST;

DRUG ADMINISTRATION; DRUG ANTAGONISM; HUMAN; NAUSEA; REVIEW; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; CISPLATIN; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; HUMANS; ISONIPECOTIC ACIDS; ISOQUINOLINES; MORPHOLINES; NAUSEA; QUINUCLIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, NEUROKININ-1; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; VOMITING;

EID: 56149116645     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3282f44a75     Document Type: Review

References (36)

1. Roila F, Hesketh PJ, Herrstedt J, et al. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17:20-28.
2. Einhorn LH, Rapoport B, Koeller J, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005; 13:112116.
3. Kris MG, Hesketh PJ, Sommerfield MR, et al. American Society of Clinical Oncology Guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24:2932-2942.
4. Herrstedt J, for the ESMO Guidelines Task Force. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2007; 18 (Suppl 2):ii83-ii85.
5. Bremer K, on behalf of the Granisetron Study Group. A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. Eur J Cancer 1992; 28A:1018-1022.
6. The Granisetron Study Group. The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. J Cancer Res Clin Oncol 1993; 119:555-559.
7. Rath U, Upadhyaya BK, Arechavala E, et al. Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 1993; 50:168172.
8. Sledge GW, Einhorn LH, Nagy C, House K. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992; 70:2524-2528.
9. Noble A, Bremer K, Goedhals D, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-dayfractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994; 30A:1083-1088.
10. Handberg J, Wessel V, Larsen L, et al. Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapy. Support Care Cancer 1998; 6:63-67.
11. Fauser AA, Pizzocaro G, Schueller J, et al. A double-blind, randomized, study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer 2000; 8:49-54.
12. Herrstedt J, Sigsgaard TC, Nielsen HA, et al. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 2007; 15:417-426. A randomized, double-blind study in patients treated with multiple cycles of 5-day cisplatin-based chemotherapy. Tropisetron plus metopimazine was superior to tropisetron alone in maintenance of antiemetic control during four cycles of chemotherapy and in the protection of delayed nausea and vomiting in multiple-day chemotherapy.
13. Einhorn LH, Brames MJ, Dreicer R, et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007; 15:1293-1300.
14. Einhorn LH, Brames JM. Emetic potential of daily oral etoposide. Support Care Cancer 2006; 14:1262-1265.
15. Sorbe B. Tropisetron in the prevention of chemotherapy-induced nausea and vomiting. The Nordic experience. Ann Oncol 1993; 4 (Suppl 3):S39-S42.
16. Wet de M, Falkson G, Rapoport BL. Repeated use of granisetron in patients receiving cytostatic agents. Cancer 1993; 71:4043-4049.
17. de Wit R, Schmitz PIM, Verweij J, et al. Analysis of cumulative probabilities show, that the efficacy of 5-HT 3 antagonist prophylaxis is not maintained. J Clin Oncol 1996; 14:644-651.
18. de Wit R, van den Berg H, Burghouts J, et al. Initial high antiemetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 1998; 77:1487-1491.
19. Soukop M, McQuade B, Hunter E, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 1992; 49:295-304.
20. Sigsgaard TC, Herrstedt J, Andersen LJ. Granisetron compared with prednisolone plus metopimazine as antiemetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer1999; 80:412418.
21. Sigsgaard TC, HerrstedtJ, Handberg J, et al. Ondansetron plusmetopimazine compared with ondansetron plus metopimazine plus prednisolone as anti- emetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 2001; 19:2091 -2097.
22. Herrstedt J, Muss HB, WarrDG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nauseaand emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005; 104:1548 -1555.
23. de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK 1antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cyclesofcisplatin-based chemotherapy. J Clin Oncol 2003; 21:4105-4111.
24. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK 1 antagonist aprepitant given with standard antiemetics provided protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy: acombined analysis of 2 randomized, placebocontrolled trials. Eur J Cancer 2004; 40:403-410.
25. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitantfor the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23:2822-2830.
26. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK -] antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97:2290-3000.
27. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21:4112-4119.
28. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nauseaand vomiting: resultsfrom a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97:3090-3098.
29. Cubeddu LX, Hofmann IS, Fuenmayor NT, Malave JJ. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992; 66:198-203.
30. Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol 1993; 33:691 - 697.
31. du Bois A. Role of serotonin in the pathophysiology of chemotherapy-induced emesis [PhD thesis, in German]. Freiburg: Albert-Ludwigs-Universitat; 1996.
32. Andrews PLR, Bhandari P, Davis CJ. Plasticity and modulation of the emetic reflex. In: Bianchi AL, Grelot L, Miller AD, King GL, editors. Mechanisms and control of emesis. Montrouge, France: John Libbey Eurotext Ltd; 1992.
33. Van den Berkmortel F, de Wit R, de Rooy J, DeMulder P. Osteonecrosis in patients with testicular tumours treated with chemotherapy. Neth J Med 2004; 62:23-27.
34. Gralla RJ, Lichinitser M, van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14:1570-1577.
35. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT 3 receptor antagonist. Cancer 2003; 98:2473-2482.
36. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 2007; 15:1285-1291. This study proposes the use of combining three new antiemetic agents - palonosetron, aprepitant and olanzapine - in the prevention of emesis in multiple-day chemotherapy. A randomized study is warranted.